Considering drug MoA when selecting SLE mouse models for preclinical efficacy studies

Lupus is an autoimmune disease in which the host’s immune system attacks its own tissues, causing inflammation and tissue damage in organs including the joints, skin, brain, lungs, kidneys, and blood vessels. It significantly affects a person's physical wellbeing and quality of life. Systemic lupus erythematosus (SLE) is one of the most common types of lupus and is characterized by the production of antibodies against autologous double-stranded DNA (dsDNA) molecules, which conveniently serves as a diagnostic and prognostic marker for SLE. Efforts have already been made to understand the causes and develop potential treatments for lupus.

When selecting SLE mouse models for preclinical efficacy studies, pathogenic mechanisms of mouse models and the drug’s mechanism of action (MoA) are key factors which need to be taken into account.

In this webinar, we will discuss:

• Pathogenic mechanisms in systemic lupus erythematosus

• Current and future therapies for SLE

• Selection of a preclinical animal model for SLE drug efficacy studies based on an MoA analysis

PDT 8:00 am | CDT 10:00 am | EDT 11:00 am | CEST 17:00 pm, April 28^th, 2023